WSTAM
GSK icon

Wilbanks Smith & Thomas Asset Management’s GSK GSK Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$598K Sell
13,950
-274
-2% -$11.3K 0.02% 320
2023
Q4 		$527K Sell
14,224
-825
-5% -$29.6K 0.02% 328
2023
Q3 		$546K Sell
15,049
-29
-0.2% -$1.03K 0.02% 298
2023
Q2 		$537K Sell
15,078
-356
-2% -$12.8K 0.02% 302
2023
Q1 		$549K Buy
15,434
+620
+4% +$21.7K 0.02% 290
2022
Q4 		$521K Sell
14,814
-983
-6% -$32.7K 0.02% 303
2022
Q3 		$465K Sell
15,797
-30,329
-66% -$1.15M 0.02% 298
2022
Q2 		$2.51M Buy
46,126
+2,706
+6% +$149K 0.11% 135
2022
Q1 		$2.45M Buy
43,420
+14,124
+48% +$767K 0.1% 137
2021
Q4 		$1.61M Buy
29,296
+5,390
+23% +$280K 0.06% 188
2021
Q3 		$1.14M Buy
23,906
+1,723
+8% +$86.5K 0.04% 210
2021
Q2 		$1.1M Buy
22,183
+3,566
+19% +$171K 0.04% 215
2021
Q1 		$831K Buy
18,617
+1,931
+12% +$87.6K 0.04% 229
2020
Q4 		$768K Sell
16,686
-172
-1% -$7.9K 0.04% 218
2020
Q3 		$793K Sell
16,858
-95
-0.6% -$4.76K 0.04% 193
2020
Q2 		$864K Sell
16,953
-1,101
-6% -$56.5K 0.05% 173
2020
Q1 		$855K Buy
18,054
+2,085
+13% +$111K 0.06% 168
2019
Q4 		$938K Buy
15,969
+3,828
+32% +$213K 0.06% 180
2019
Q3 		$648K Sell
12,141
-417
-3% -$21.5K 0.04% 195
2019
Q2 		$628K Buy
12,558
+974
+8% +$48.9K 0.04% 204
2019
Q1 		$605K Buy
11,584
+2,433
+27% +$122K 0.04% 215
2018
Q4 		$437K Buy
9,151
+3,720
+68% +$183K 0.03% 217
2018
Q3 		$273K Buy
+5,431
New +$276K 0.02% 324
2017
Q4 		– Sell
-5,430
Closed -$276K – 351
2017
Q3 		$276K Buy
5,430
+1,212
+29% +$61.5K 0.02% 262
2017
Q2 		$227K Sell
4,218
-1,168
-22% -$62.3K 0.02% 288
2017
Q1 		$284K Sell
5,386
-593
-10% -$30.1K 0.02% 247
2016
Q4 		$288K Sell
5,979
-311
-5% -$15.4K 0.03% 236
2016
Q3 		$339K Buy
6,290
+149
+2% +$8.17K 0.03% 204
2016
Q2 		$333K Sell
6,141
-267
-4% -$14.1K 0.03% 207
2016
Q1 		$325K Sell
6,408
-52
-0.8% -$2.59K 0.04% 209
2015
Q4 		$326K Sell
6,460
-822
-11% -$41.9K 0.03% 197
2015
Q3 		$350K Buy
7,282
+882
+14% +$45.9K 0.05% 182
2015
Q2 		$333K Sell
6,400
-1,202
-16% -$67.7K 0.03% 223
2015
Q1 		$439K Sell
7,602
-163
-2% -$9.35K 0.04% 184
2014
Q4 		$415K Sell
7,765
-453
-6% -$25.3K 0.04% 196
2014
Q3 		$472K Sell
8,218
-1,496
-15% -$91.7K 0.05% 170
2014
Q2 		$649K Buy
9,714
+416
+4% +$28.2K 0.07% 147
2014
Q1 		$621K Sell
9,298
-144
-2% -$9.73K 0.07% 148
2013
Q4 		$630K Sell
9,442
-1,079
-10% -$70K 0.07% 144
2013
Q3 		$660K Buy
10,521
+1,280
+14% +$82.4K 0.09% 134
2013
Q2 		$577K Buy
+9,241
New +$587K 0.09% 135

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's GSK Position: Q1 2024 in Review

Wilbanks Smith & Thomas Asset Management reduced its GSK (GSK) stake by 1.9% in Q1 2024, selling an estimated $11.3K and leaving 13,950 shares worth $598K. The position accounts for 0.02% of the portfolio, ranked #320.

Wilbanks Smith & Thomas Asset Management first reported a position in GSK in Q2 2013 and has held it in 41 quarters since. The position peaked at $2.51M in Q2 2022. 911 funds tracked by Wall St. Rank hold GSK as of Q1 2024.

  • Wilbanks Smith & Thomas Asset Management held 13,950 shares of GSK worth $598K as of Q1 2024.
  • Wilbanks Smith & Thomas Asset Management sold 274 GSK shares in Q1 2024, an estimated $11.3K.
  • GSK made up 0.02% of Wilbanks Smith & Thomas Asset Management's portfolio in Q1 2024, its #320 holding.
  • Wilbanks Smith & Thomas Asset Management first reported a position in GSK in Q2 2013 and has held it in 41 quarters since.
  • Wilbanks Smith & Thomas Asset Management's GSK position peaked at $2.51M in Q2 2022.
  • 911 funds tracked by Wall St. Rank held GSK as of Q1 2024.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2024, filed 7 May 2024.